Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 90

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 90
---
 in October 2024, and (vi) as financial advisor for the Warrant Inducement consummated in February 2025, pursuant to which
WallachBeth received cash compensation and warrants. See the section entitled “The Private Placement” above for more information
about the compensation received in connection with the Warrant Inducement.

The table below lists the Selling Stockholders and
provides information regarding their beneficial ownership of shares of Common Stock by each of the Selling Stockholders. The second column
lists the number of shares of Common Stock beneficially owned by each of the Selling Stockholders, based on its ownership of the shares
of Common Stock, the Common Warrants and shares of Comon Stock issuable upon exercise of warrants acquired in offerings prior to the transactions
described in the section entitled, “The Private Placement,” as of April 10, 2025, assuming exercise of the Common Warrants
held by the Selling Stockholders on that date, without regard to any limitations on exercises. The third column lists the maximum number
of shares of Common Stock being offered by this prospectus by the Selling Stockholders, also without regard to any limitations on exercises.

This prospectus generally covers the resale of the
maximum number of shares of Common Stock issuable upon exercise of the Common Warrants, determined as if the outstanding Common Warrants
were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC,
each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the
registration right agreement, without regard to any limitations on the exercise of the Common Warrants. The fourth and fifth columns assume
the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus.

Under the terms of the Common Warrants, the Selling
Stockholders may not exercise the Common Warrants to the extent such exercise would cause such Selling Stockholder, together with its
affiliates and attribution parties, to beneficially own a number of shares of Common Stock that would exceed 4.99%, of our then outstanding
Common Stock following such exercise, excluding for purposes of such determination shares of Common Stock issuable upon exercise of such
warrants which have not been exercised. The number of shares in the second and third columns do not reflect this limitation. The Selling
Stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

| Name of Selling Stock